GlassScriptPhysician profile
Allan Schwadron
NPI 1265450878
$10,893.22
in general payments reported to CMS, 2019-2025
40 companies · $1,061 in 2025
The $1,061 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,767 · 2020: $1,688 · 2021: $2,319 · 2022: $1,488 · 2023: $1,417 · 2024: $1,153 · 2025: $1,061.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,631.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,630.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,166.42 | 2019-2022 | |
| Actelion Pharmaceuticals US, INC. | $1,158.69 | 2019-2024 | Uptravi, Opsumit |
| Glaxosmithkline, LLC. | $1,115.27 | 2019-2024 | Arexvy, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $1,086.54 | 2019-2025 | Airsupra, Farxiga, Wainua |
| Amgen INC. | $1,073.73 | 2019-2025 | Repatha, Repatha |
| Sanofi-Aventis U.S. LLC | $507.96 | 2019-2023 | |
| Esperion Therapeutics, INC. | $456.10 | 2020-2021 | |
| Pfizer INC. | $407.09 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $398.67 | 2022-2025 | Verquvo, Capvaxive |
| Inspire Medical Systems, INC. | $357.43 | 2023-2025 | Inspire |
| E.R. Squibb & Sons, L.L.C. | $339.33 | 2022-2025 | Camzyos, Eliquis |
| Novartis Pharmaceuticals Corporation | $289.98 | 2020-2024 | |
| Novo Nordisk INC | $285.59 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Lantheus Medical Imaging, INC. | $251.26 | 2019-2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $228.79 | 2022-2025 | Lifevest |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allan Schwadron listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.